Connect with us

Conference Events

CBD Science and Health Implications Webinar by NASEM is October 17



CBD Science and Health Implications Webinar by NASEM is October 17
  • The webinar will not involve any officials from the Food and Drug Administration.
  • Multiple members of Congress have pushed for the FDA to implement clear regulations for cannabis business and the use of this substance in health supplements.

Even with the legalization of hemp and its derivatives, which includes CBD, there is a large portion of the country that still doesn’t quite have an understanding of what it is and isn’t. To make some of this information a little easier to comprehend, the National Academies of Science, Engineering and Medicine (NASEM) has chosen to hold a webinar, which will touch on the science behind CBD, as well as its health implications.

The NASEM dates back to a legislation signed in 1863 by President Abraham Lincoln, and federal agencies are responsible for funding it. The webinar is planned to last one hour, as the NASEM discusses “the current and emerging scientific knowledge on and the potential health implications” of CBD.

In a notice for the upcoming webinar, NASEM stated that the speakers will be discussing “challenges to defining CBD, the foundational principles associated with CBD, and specific issues pertaining to cannabinoids in the food supply.”

The 2018 Farm Bill made CBD legal last year, but one of the big issues in the industry now is that the Food and Drug Administration has yet to establish regulations for CBD, regarding how it can be lawfully marketed in dietary supplements and foods. Congress has understandably taken it upon themselves to push for the FDA to move along the process, and there are lawmakers from both sides that have stated that the entire point of the agriculture legislation is to allow the products to be sold.

Until the FDA makes some changes, that end goal cannot happen. A total of 26 lawmakers recently signed a letter that stressed the “significant regulatory and legal uncertainty” for anyone involved in the industry. The leader of the hemp legalization legislation, Senate Majority Leader Mitch McConnell, has also pushed for rules to be established for CBD businesses.

The webinar isn’t likely to see any FDA officials in attendance, as none of listed in the event. However, Renée Johnson of the Congressional Research Service will be involved. Roger Clemens of the University of California School of Pharmacy and Daniele Piomelli of the Institute for the Study of Cannabis at the University of California will also attend.

Andrew is a full-time professional writer in Canada with over 8 years of esteemed experience. He is one of the best cannabis health researchers, polished legal investigators and active CBD news reporters we have at TOC. While being featured in hundreds of health, technology, science, and even bitcoin publications; Andrew's now on the frontline of the Canadian cannabis culture and will continue breaking down everything so easily your grandma can understand hemp and CBD.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.